Novartis received approval for Coartem Baby, the first malaria treatment for infants under 9.9 pounds. Collaboration with Medicines for Malaria Venture led to its development. Previously, malaria treatments were only available for children six months and older, leaving a treatment gap for younger infants. The new treatment aims to address high malaria infection rates in Africa, with significant deaths reported. Novartis emphasizes its commitment to combat malaria, allowing vulnerable newborns and infants to access necessary care.
"Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve."
"For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most."
Collection
[
|
...
]